The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease - PubMed
3 days ago
- #ctDNA
- #Minimal Residual Disease
- #Breast Cancer
- Study evaluates ctDNA as a biomarker for treatment response in HER2-positive and TNBC breast cancer patients.
- Primary objective to determine if negative predictive value (NPV) of post-NAT ctDNA for pCR was ≥90% was not met (NPV 60%).
- Detectable ctDNA after NAT was prognostic for recurrence (HR 8.9) and after surgery identified high-risk patients (HR 128).
- ctDNA-negative patients post-surgery had 94% 5-year invasive disease-free survival (IDFS).
- Findings support ctDNA-guided therapeutic strategies for de-escalation and escalation.